Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sapacitabine: Preliminary Phase II data

Preliminary data from a U.S. Phase II trial in 5 patients showed 1 partial response and 4 cases

Read the full 183 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE